On Thursday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced results from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR), a disorder that causes pain in the lower back and hip that radiates down the back of the thigh into the leg. The study met its primary endpoint with a statistically significant and clinically meaningful reduction in pain on the numeric pain rating scale (NPRS). The suzetrigine arm sho…

Benzinga

New York

United States

Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data? - Vertex Pharmaceuticals (NASDAQ:VRTX)

Ad Fontes Media

Media Bias/Fact Check

The Boston drugmaker announced results of a midstage trial of its experimental painkiller in chronic back pain, but investors weren't sold.

All Sides

The Business Journals

Advance Publications

Vertex’s non-opioid painkiller meets trial goal — but investors aren’t sold

Vertex stock plummeted Thursday after the company's pain drug proved it's no better than a placebo in patients with lower back and hip pain. The post Vertex Plunges 10% After Its Non-Opioid Pain Drug Flops In Lower Back Pain appeared first on Investor's Business Daily.

Investor's Business Daily

Vertex Plunges 10% After Its Non-Opioid Pain Drug Flops In Lower Back Pain

The pain drug, called suzetrigine, did not lead to a bigger drop in patients' pain scores than a placebo did.

STAT

The Boston Globe

Boston

Suffolk County

Massachusetts

Vertex touts pain drug results, but medicine does not outperform placebo in sciatica study

It’s clear that CrossFit provides a range of benefits, and recently, researchers set out to explore if it could also reduce back pain and the need for pain medication.  The post Can CrossFit help with pain and reduce the need for pain medication? New Study appeared first on The Manual.

The Manual

Can CrossFit help with pain and reduce the need for pain medication? New Study

– Treatment with the highly selective NaV1.8 pain signal inhibitor suzetrigine met the primary endpoint with a statistically significant and clinically meaningful 2.02 point within-group reduction from baseline in the Numeric Pain Rating Scale (NPRS) – – Placebo arm showed similar within-group reduction in NPRS – – Suzetrigine was generally well tolerated – – Advancement to Phase 3 in painful lumbosacral radiculopathy planned, pending discussion…

pipelinereview

Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy - Pipelinereview

Vertex Pharmaceuticals Expands Treatment Options for Cystic Fibrosis and Advances Pain Management Approaches 'BOSTON, MA' '' Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has made significant strides in its commitment to improving the lives of individuals with cystic fibrosis (CF) and addressing acute pain through recent U.S. Food and Drug Administration (FDA) approvals and new drug applications (NDAs). This article delves into the details …

csimarket.com

# Vertex Pharmaceuticals Expands Cystic Fibrosis Treatment Options and Innovates Pain Management with Groundbreaking ...

Vertex Pharmaceuticals announced highly anticipated results from a Phase 2 trial Thursday morning in a chronic pain condition, saying its non-opioid pain pill suzetrigine met the primary endpoint and that it would be moving into a Phase 3 study. But the pill appeared to perform similarly to placebo.

Endpoints News

Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

A trial of Vertex's suzetrigine in neuropathic back pain met its primary objective, but shares in the company fell as investors reacted to the data

Pharmaphorum

Vertex weakens after neuropathic pain trial reads out

Vertex said the Phase II trial met its primary endpoint, however there was only a minor difference to placebo.

Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data? - Vertex Pharmaceuticals (NASDAQ:VRTX)

Coverage Details

Give the gift of Perspective

Bias Distribution

Ownership

Similar News Topics

Similar News Topics